Medication During Pregnancy
Bakker MK, Kerstjes-Frederkse WS, Buys CHCM, de Walle HEK, de Jong-van den Berg LTW (in press), "First Trimester Use of Paroxetine and Congenital Heart Defects: A Population-Based Case-Control Study. Accepted Birth Defects Research part A.
Marleen M.H.J. van Gelder, Iris A.L.M. van Rooij, Richard K. Miller, Gerhard A. Zielhuis, Lolkje T.W. de Jong-van den Berg, and Nel Roeleveld Teratogenic mechanisms of medical Drugs Human Reproduction Update, 2010 Vol.00, No.1 pp. 1–17 doi:10.1093/humupd/dmp052
Gouverneur B.J.G.M., de Jong-van den Berg L.T.W. Insulin analogs and pregnancy, What is known in 2009. PW wetenschappelijk platform.2009;3;42-48 (Dutch)
Luteyn M. Pregnancy prevention programmes in the context of teratogenic risks. Master thesis RUG Groningen 2009
Bakker MK, de Walle HEK, de Jong-van den Berg LTW. Reply to Martínez-Frías and Rodríguez-Pinilla. Birth Defects Research (part A) 2008;82:175-(letter).
de Jong-van den Berg LTW. Monitoring of the folic acid supplementation program in the Netherlands. Food and Nutrition Bulletin 2008;29(2):210-213.
Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LTW. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-722.
Bakker MK, Kolling P, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. British Journal of Clinical Pharmacology 2008;65(4):600-606.
Jentink J, van de Vrie-Hoekstra N, de Jong-van den Berg LTW, Postma MJ. Economic evaluation of folic acid food fortification in The Netherlands. European Journal of Public Health 2008;18(3):270-274.
Vroom F, van den Berg PB, de Jong-Van den Berg LTW. Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful? British Journal of Clinical Pharmacology 2008;65(2):275-276.
Vroom F, van Roon EN, van den Berg PB, Brouwers JRBJ, de Jong-van den Berg LTW. Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy - a descriptive study. Pharmacoepidemiology and Drug Safety 2008;17(1):52-61.
Vroom F, van de Laar MAJF, van Roon EN, Brouwers JRBJ, de Jong-van den Berg LTW. Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists. Journal of Clinical Pharmacy and Therapeutics 2008;33(1):39-44.
Bakker MK, de Walle HEK, Dequito A, van den Berg PB, de Jong-van den Berg LTW. Selection of controls in case-control studies on maternal medication use and risk of birth defects. Birth Defects Research (part A) 2007;79:652-656
Bakker M, Jentink J, Vroom F, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG An International Journal of Obstetrics and Gynaecology 2006;113:559-68.
Krapels I, Zielhuis G, Vroom F, de Jong-van den Berg LTW, Kuijpers-Jagtman A-M, Mink van der Molen A, Steegers-Theunissen R. Periconceptional health and lifestyle factors of both affect the risk of live-born children with orofacial clefts. Birth Defects Research 2006;76(part A):613-20.
Meijer WM, Werler MM, Louik C, Hernandez-Diaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down Syndrome? Birth Defects Research (part A) 2006;Clinical and molecular Teratology 76:714-7.
Meijer WM, de Jong-van den Berg LTW, van den Berg M, Verheij J, de Walle HEK. Clomiphene and Hypospadias on a detailed level: signal or change? Birth Defects Research 2006;76(a):249-52.
Meijer WM, Cornel MC, Dolk H, de Walle HEK, Armstrong N, de Jong-van den Berg LTW. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. Pharmacoepidemiology and Drug Safety 2006;15:675-82.
Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg LTW, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62(10):863-70.
Vroom F, de Walle HEK, van de Laar MAFJ, Brouwers JRBJ, de Jong-van den Berg LTW. Disease-modifying antirheumatic drugs in pregnancy. Drug Safety 2006;29(10):845-63.
Veurink M, Koster M, de Jong-van den Berg LTW. The history of DES, lessons to be learned. Pharmacy World & Science 2005;27:139-43.
Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LTW. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. European Journal of Obestetrics & Gynecology 2004;114:182-8.
Schirm E, Tobi H, de Jong-van den Berg LTW. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. Journal of Clinical Epidemiology 2004;57:737-41.
Schirm E, Pedersen L, Tobi H, Nielsen GL, Sørensen HT, de Jong-van den Berg LTW. Drug use among fathers around time of conception: two register based surveys from Denmark and The Netherlands. Pharmacoepidemiology and Drug Safety 2004;13:609-13.
van Driel D, Wesseling J, ter Huurne K, Geven-Boere LM, Rosendaal FR, van der Veer E, de Jong-van den Berg LTW. Adherence to a guideline for coumarins in pregnancy. Pharmacy World & Science 2004;26:297-300.
Pradat P, Francannet C, Harris JA & Robert E (2003) The Epidemiology of Cardiovascular Defects, Part I: A Study Based on Data from Three Large Registries of Congenital Malformations. Pediatr Cardiol, 24: 195-221
Reefhuis J, de Jong-van den Berg LTW, Cornel MC. The Use of Birth Defect Registries for Etiological Research: A Review. Community Genet 2003; 5:13-32
Dolk H, McElhatton P (2002) Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medications. Journal of Medical Genetics, 39, 243-244
Olsen J, Czeizel A, Sorensen HT, Nielsen GL, Irgens LM, de Jong-van den Berg LTW et al. How Do We Best Detect Toxic Effects of Drugs Taken During Pregnancy?: A EuroMap Paper. Drug Safety 2002; 25:21-32
Reefhuis J, de Jong-van den Berg LTW, Cornel MC. The Use of Birth Defect Registries for Etiological Research: a Review. Community Genet 2002; 5:13-32
Oleson C, Sondergaard C, Thrane N, Nielsen GL, Jong-van den Berg LTW de, Olsen J for the EuroMAP Group. Do Pregnant Women Report Use of Dispensed Medications? Epidemiology 2001; 12: 497-501
Reefhuis J, de Walle HEK, de Jong-van den Berg LTW, Cornel MC, EuroMAP-group. Additional information from parental questionnaires and pharmacy records for registration of birth defects. Eur J Epidemiology 2000;16:329-336.
de Jong-van den Berg, L.T.W. de, Feenstra, N., Sorensen, H.T., Cornel, M.C., Euromap Group, Improvement of Drug Exposure Data in a Registration of Congenital Anomalies. Pilot-Study: Pharmacist and Mother as Sources for Drug Exposure Data During Pregnancy, Teratology 1999; 60: 33-6
de Vigan C, De Walle HE, Cordier S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. OECM Working Group. Occupational Exposures and Congenital Anomalies. J Clin Epidemiol 1999 52: 977-82.
Oleson, C., Sorensen, H.T., Jong-van den Berg, L.T.W. de, Olsen, J., Steffensen, F.H., The Euromap Group, Prescribing during pregnancy and lactation with reference to the Swedish classification system, Acta Obstet et Gynecol Scand 1999; 78: 686-92
Oleson, C., Steffensen, F.H., Nielsen, G.L., Jong-van den Berg, L.T.W. de, Olsen, J., Sørensen, H.T., The Euromap Group, Drug use in first pregnancy and lactation: a population-based survey among Danish women, Eur J Clin Pharmacol 1999; 55: 139-144
De Vries CS, De Walle HEK, Cornel MC, De Jong-van den Berg LTW. Registration of drug use in a birth defect monitoring system: a priority worthy of emphasis! Int J Risk Saf Med 1993;4:27-34.